Leukemia

Children With Down Syndrome at Higher Risk for Leukemia

Risk particularly high for acute myeloid leukemia before age 5 years.

Characteristics of Immunoglobulin Supplementation in B-Cell Acute Lymphoblastic Leukemia

By

Patricia Chaney

Researchers sought to determine what characteristics may drive physician decisions to give immunoglobulin supplementation for patients with B-cell ALL.

Combination Platelet and Blast Counts Predicts Outcomes in Pediatric Acute Lymphoblastic Leukemia

By

Jonathan Goodman, MPhil

Researchers sought to determine whether combination platelet and blast counts would be a helpful predictive model for pediatric patients with ALL.

NR3C1 Mutations May Drive Glucocorticoid Resistance in Patients With Acute Lymphoblastic Leukemia

By

Jonathan Goodman, MPhil

Researchers sought to determine whether NR3C1 mutations might influence glucocorticoid resistance and treatment outcomes in pediatric patients with ALL.

Quizartinib Combination Therapies Effective in Frontline and First-Salvage Therapy in AML

By

Ariela Katz

Researchers sought to determine whether quizartinib-based combination therapies would be safe and effective treatment options for patients with AML.

Short-Term 6-TG Exposure During Treatment for Pediatric ALL Associated With Hepatic SOS

By

Colby Stong

Investigators analyzed the association between hepatic SOS and short-term application of 6-TG in 3983 pediatric ALL patients.

Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL

By

Christina Bennett, MS

A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.

Diet, Exercise Intervention Explored in Children With B-ALL

Reduction in fat gain not seen in overall cohort, but stratified analysis showed benefit among those overweight, obese at baseline.

Whole-Genome Sequencing Shows Promise for Risk Stratification in AML, MDS

By

Jonathan Goodman, MPhil

Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.

Low-Dose Anthracycline in Induction Shows Better Safety in Patients With Acute Promyelocytic Leukemia

By

Vicki Moore, PhD

Researchers sought to determine whether a lower dose of anthracycline would have the same efficacy and better safety as standard dosage in patients with APL.

Certain Mutations May Be Associated With Infection Risk for Patients With Chronic Lymphocytic Leukemia

By

Patricia Chaney

Researchers sought to determine factors that may impact infection risk in patients with CLL.

Posttraumatic Stress Disorder Symptoms Seen in Patients With Acute Myeloid Leukemia

By

Vicki Moore, PhD

Researchers investigated whether there may be a trend of patients with AML developing symptoms of PTSD.

High Cortactin, HS1 Levels Predict Worse Survival in Patients With B Cell Acute Lymphoblastic Leukemia

By

Jonathan Goodman, MPhil

Researchers sought to determine whether high cortactin and HS1 expression may be linked with poorer prognosis for patients with B-ALL.

Anti-CD20 Antibody Improved Response to Ibrutinib in High-Risk R/R CLL

By

Leah Lawrence

Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.

BTK Inhibitors for CLL Lower Response to Some Vaccines

By

Andrea S. Blevins Primeau, PhD, MBA

A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.

Pre-Transplantation MRD Status Predicts Survival in Acute Leukemia

By

Jonathan Goodman, MPhil

Researchers sought to determine whether MRD status could be a helpful prognostic tool for survival in patients with acute leukemia prior to allo-HSCT.

Case Study Shows Potential Protective Effect of TKI Therapy for Chronic Myeloid Leukemia

By

Vicki Moore, PhD

A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.

Acute Kidney Injury Seen With Induction Chemotherapy for Acute Myeloid Leukemia

By

Vicki Moore, PhD

Researchers sought to determine the incidence and risk factors for acute kidney in patients with AML who are undergoing induction chemotherapy.

Dasatinib, Nilotinib Effective Second-Line Therapy for Chronic Myeloid Leukemia

By

Patricia Chaney

Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.

Cytogenetics Predict Outcomes to Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

By

Patricia Chaney

Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.

The Role of Early Intervention in the Treatment of Early-Stage CLL

By

Caleb Rans, PharmD

There is a need for further investigation of early intervention options for patients with early-stage CLL.

Moxetumomab Pasudotox Shows Durable Responses for Patients With Relapsed/Refractory Hairy Cell Leukemia

By

Vicki Moore, PhD

Researchers sought to see whether long-term results of a trial involving moxetumomab pasudotox would have durable response for patients with relapsed/refractory HCL.

Blinatumomab Improved Survival for Patients With B-Cell ALL, but Not Significantly

By

Patricia Chaney

Researchers sought to determine if immunotherapy including blinatumomab could improve disease-free survival for patients with B-cell ALL.

Lenalidomide Maintenance Therapy Linked With B-Cell Acute Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia

By

Vicki Moore, PhD

Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.

TBI Conditioning Before Stem Cell Transplantation Improves Survival in Pediatric ALL

By

Patricia Chaney

Researchers sought to determine whether pediatric patients with ALL would have better OS if they received TBI prior to HSCT.

Azacitidine Plus Venetoclax Is Not Cost-Effective for Some Patients With AML

By

Katie Kosko

Cost-effectiveness model was developed to compare costs and other factors of azacitidine/venetoclax combination with azacitidine alone in patients with AML.

BH3 Profiling Finds Ruxolitinib Plus Venetoclax Promising for T-Cell Prolymphocytic Leukemia

By

Patricia Chaney

Researchers assessed the effectiveness of belinostat, ruxolitinib, and ibrutinib used to treat T-PLL mitochondrial priming and drug sensitivity.

Next-Generation Approaches to Karyotyping in Acute Myeloid Leukemia

By

Vicki Moore, PhD

Researchers revisited the techniques traditionally used to assess CNAs and translocations in routine AML diagnostics to challenge the recommended CCA.

Clinical Trial: Investigational BTK Inhibitor Undergoes Investigation in CLL, B-Cell Lymphoma

By

Rachel Narozniak, MA

Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.

Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML

By

Rachel Narozniak, MA

Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).

Genetic Mutations May Add to Racial Disparity in Child B-ALL

Increased incidence of IKZF1 deletion and IGH-CRLF2 translocation seen in Hispanic/Latino children with B-ALL.

Leukemia: Fact Sheet for Patients

By

Steve Fiorillo

Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?

Flotetuzumab Therapy for Relapsed/Refractory Acute Myeloid Leukemia

By

Vicki Moore, PhD

Researchers sought to find out if flotetuzumab shows activity with an acceptable safety profile in patients with acute myeloid leukemia and primary induction failure or early relapse.

Thymoglobulin as GVHD Prophylaxis in AML Conditioning Regimens

By

Patricia Chaney

Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.

Fractionated Gemtuzumab Ozogamicin Not Linked With Increased VOD/SOS Risk in Acute Myeloid Leukemia

By

Jonathan Goodman, MPhil

Among patients with de novo AML, fractionated-dose gemtuzumab ozogamicin does not appear to increase the risk of hepatic VOD/SOS after HSCT.

Study Data Detail Biological Basis for Health Disparity in Pediatric B-Cell ALL

By

Leah Lawrence

Investigators of this single-center analysis compare the incidence of CRLF2 rearrangement and IKZF1 deletion in Hispanic/Latino vs non-Hispanic/Latino children with B-cell acute lymphoblastic leukemia (B-ALL).

Fractionated Busulfan Improves NRM and Survival in AML and MDS

By

Jonathan Goodman, MPhil

Researchers compare fractionated busulfan myeloablative conditioning to traditional RIC in elderly patients undergoing allogeneic hematopoietic stem cell transplantation.

Pyridoxine Plus Pyridostigmine Beneficial for Neurotoxicity in ALL

By

Patricia Chaney

A team of investigators prospectively evaluated pediatric patients with ALL to determine the effectiveness of pyridoxine (vitamin B6) plus pyridostigmine therapy for vincristine-induced neurotoxicity.

American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults

By

Julie Scott, ANP-BC, AOCNP

This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.

Survey Reveals Varied Treatment of VTE in Pediatric Acute Lymphocytic Leukemia

By

Jonathan Goodman, MPhil

A team of researchers identified a lack of standardized practices for treating venous thromboembolism among pediatric patients with acute lymphocytic leukemia.

Measurable Residual Disease Is Prognostic Factor Before Transplantation in First and Second Remission of Ph+ ALL

By

Patricia Chaney

A team of investigators evaluated the effect of measurable residual disease at time of allogeneic hematopoietic cell transplantation in patients with ALL undergoing transplantation during either first or second complete remission.

Blinatumomab as Salvage Therapy for Pediatric R/R B-Cell Precursor Acute Lymphoblastic Leukemia

By

Lauren Dembeck, PhD

Among pediatric patients with relapsed or refractory acute lymphoblastic leukemia, the use of blinatumomab may provide encouraging response rates.

Sodium Bicarbonate Associated With Enhanced GVL Effect in AML Following Allo-HSCT

By

Caroline Seydel

Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.

Combination Sitagliptin, Tacrolimus, Sirolimus for Prophylaxis of Acute Graft-vs-Host-Disease

By

Patricia Chaney

Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.

Reduced-Intensity Conditioning May Not Improve Post Allogeneic HSCT Outcomes in AML

By

Patricia Chaney

A sequenced reduced-intensity conditioning regimen may not improve outcomes for patients with acute myeloblastic leukemia and myelodysplasia after allogeneic stem cell transplantation.

Uncertainties Surround Optimal Dosing of Cytarabine in AML

By

Susan Moench, PhD, PA-C

This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).

Outcomes of Adding a Fourth Chemotherapy Course in AML

By

Patricia Chaney

For patients with acute myeloid leukemia, a total of 4 courses of chemotherapy may improve relapse rates but not overall survival, compared with 3 total courses of treatment.

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML

By

Christina Bennett, MS

Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.

Idelalisib Does Not Increase Risk for Bleeding in Patients With CLL, Indolent NHL Receiving Anticoagulation/Antiplatelet Therapy

By

Susan Moench, PhD, PA-C

This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.

Oral Azacitidine to Improve Survival in First-Remission Acute Myeloid Leukemia

By

Patricia Chaney

Maintenance therapy with oral azacitidine leads to longer overall survival in older patients with acute myeloid leukemia.

Total Body Irradiation vs Chemotherapy Conditioning for Pediatric Acute Lymphoblastic Leukemia

By

Patricia Chaney

Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.